{"id":"remifentanilmntx","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle rigidity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Remifentanil acts as a mu-opioid receptor agonist in the central nervous system to produce analgesia and sedation. Methylnaltrexone is a quaternary ammonium derivative of naltrexone that antagonizes mu-opioid receptors peripherally (unable to cross the blood-brain barrier) to counteract gastrointestinal and other peripheral opioid-induced adverse effects while preserving central analgesic effects.","oneSentence":"RemifentanilMNTX is a combination of remifentanil (a potent opioid agonist) and methylnaltrexone (a peripheral mu-opioid receptor antagonist) designed to provide analgesia while reducing opioid-induced side effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:02.395Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intraoperative analgesia and sedation during anesthesia"}]},"trialDetails":[{"nctId":"NCT03283020","phase":"PHASE4","title":"Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume","status":"UNKNOWN","sponsor":"Region Örebro County","startDate":"2017-11-11","conditions":"Pharyngeal Dysfunction, Pharyngeal Swallowing","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Methylnaltrexone","Remifentanil","Relistor","Ultiva"],"phase":"marketed","status":"active","brandName":"RemifentanilMNTX","genericName":"RemifentanilMNTX","companyName":"Region Örebro County","companyId":"region-rebro-county","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RemifentanilMNTX is a combination of remifentanil (a potent opioid agonist) and methylnaltrexone (a peripheral mu-opioid receptor antagonist) designed to provide analgesia while reducing opioid-induced side effects. Used for Intraoperative analgesia and sedation during anesthesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}